Fradley MG, et al. - In this retrospective study, researchers compared the rates and risk of atrial arrhythmias (AA) in a real-world sample of cancer patients who have received ibrutinib or chemotherapy. They compared 137 patients treated with ibrutinib vs 106 patients treated with chemotherapy for B-cell malignancies. For assessing any statistically significant variations between groups, they used Fisher's exact test. According to findings, higher rates and risk of AA were observed in relation to treatment with ibrutinib vs chemotherapy. Strong evidence was generated in this study that proves ibrutinib itself is an independent risk factor for the development of incident AA. Patients treated with ibrutinib had a 5-fold increased risk of developing AA, as seen in multivariable analysis.